05 October 2010

Amsterdam Molecular Therapeutics Launches Equity Offering of up to € 15 million

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces today the launch of an equity offering by means of a private placement to certain institutional investors, other qualifying investors who subscribe for at least € 50,000 per investor in various jurisdictions, and the members of the Board of Management with the aim to raise net proceeds of € 15 million (the "Private Placement").

AMT’s key shareholders Advent Venture Partners, Gilde Healthcare Partners, Crédit Agricole Private Equity and Forbion Capital Partners, have committed to subscribe for new shares in the Private Placement for an aggregate amount of € 3.75 million. The members of the Board of Management have expressed their intention to participate in the Private Placement.

Kempen & Co and Petercam Nederland are acting as joint global coordinators and bookrunners for the Private Placement, which shall be structured as an accelerated bookbuilding process. The accelerated bookbuilding process shall start with immediate effect and is expected to close on Thursday 7 October, subject to acceleration or extension of the timetable of the Private Placement and barring unforeseen circumstances.

The issue price and number of shares to be issued pursuant to the Private Placement will be determined on the outcome of the accelerated bookbuilding process and will be announced in a subsequent press release. Payment and settlement of the new shares and their admission to trading and listing on NYSE Euronext in Amsterdam is expected to occur on October 12, 2010.

The net proceeds of the Private Placement will increase AMT’s financial flexibility and will be used to fund Glybera® through its regulatory and commercial development and to continue the development of the hemophilia and other pipeline programs.

The prospectus, which has been prepared in relation to the admission to listing and trading of the new shares, has been made generally available through the AMT website, and will be available through the website of NYSE Euronext.

There will be no offering of the new shares in the United States. The new shares will be offered outside the United States in "offshore transactions" within the meaning of, and pursuant to Regulation S. under the U.S. Securities Act of 1933, as amended.

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud